Cargando…

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer

Vascular endothelial growth factor A (VEGF-A) and intercellular adhesion molecule 1 (ICAM-1) are significant regulators of angiogenesis, an important biological process involved in carcinogenesis. Bevacizumab, an anti-VEGF monoclonal antibody (MAB), is approved for the treatment of metastatic Colore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papachristos, Apostolos, Karatza, Eleni, Kalofonos, Haralabos, Sivolapenko, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311957/ https://www.ncbi.nlm.nih.gov/pubmed/32466535 http://dx.doi.org/10.3390/ijms21113753

Ejemplares similares

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
por: Papachristos, Apostolos, et al.
Publicado: (2019)

Machine learning‐guided covariate selection for time‐to‐event models developed from a small sample of real‐world patients receiving bevacizumab treatment
por: Karatza, Eleni, et al.
Publicado: (2022)

Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review
por: Papachristos, Apostolos, et al.
Publicado: (2020)

A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients
por: Panoilia, Eirini, et al.
Publicado: (2015)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas
por: Skandalis, Spyros S, et al.
Publicado: (2011)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
por: Xu, Ran, et al.
Publicado: (2018)

Characterization and Biological Evaluation of Propolis from Poland
por: Popova, Milena, et al.
Publicado: (2017)

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
por: Pohl, Alexandra, et al.
Publicado: (2012)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer
por: Gaulin, J., et al.
Publicado: (2009)

Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
por: Hamid, Mohsin, et al.
Publicado: (2018)

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
por: Coltelli, Luigi, et al.
Publicado: (2022)

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice
por: Razenberg, L. G. E. M., et al.
Publicado: (2016)

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
por: Martins, Diana, et al.
Publicado: (2022)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
por: Moriwaki, Toshikazu, et al.
Publicado: (2021)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling of oxcarbazepine and levetiracetam during adjunctive antiepileptic therapy in children and adolescents
por: Sinha, Jaydeep, et al.
Publicado: (2021)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018)

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
por: Li, Ching-Chun, et al.
Publicado: (2018)

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)
por: Zinser-Sierra, Juan W., et al.
Publicado: (2012)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
por: Avallone, Antonio, et al.
Publicado: (2016)

Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection
por: Ghiringhelli, Francois, et al.
Publicado: (2014)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
por: Dinu, Ioana Mihaela, et al.
Publicado: (2023)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
por: Kim, Seijong, et al.
Publicado: (2022)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)
por: Iwamoto, S., et al.
Publicado: (2015)

Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours
por: Labropoulou, Vassiliki T., et al.
Publicado: (2013)

Expression of ERα, ERβ and Co-Regulator PELP1/MNAR in Colorectal Cancer: Prognostic Significance and Clinicopathologic Correlations
por: Grivas, Petros D., et al.
Publicado: (2009)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hpiil74a2bfe6c9chrrr62vrij